Faron Pharmaceuticals (LON:FARN) Presenting at the Proactive One2One Virtual Forum

We are a clinical stage biopharmaceutical company focused on treating various indications across immuno-oncology, organ injury and vascular damage. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses. We are disrupting the current treatment landscape with a novel pipeline of immune modulation based proprietary drug candidates with numerous applications tackling major unmet needs including immuno-oncology, pulmonology and organ protection following serious viral infections, as well as immune deficiency and regenerative medicine. Faron works today with tomorrow’s breakthroughs. Our main focus is on our core scientific and clinical development expertise. Working closely with our network of trusted strategic collaborators we are able to give our pipeline the greatest chances of success with a focus on improving the lives of patients suffering from devastating diseases. Based in Turku, Finland, Faron Pharmaceuticals is listed on AIM under the ticker FARN and Nasdaq First North Growth Market ("Nasdaq First North") under the ticker FARON.